# SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

> **NCT02976740** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 48 (estimated)

## Conditions studied

- Lung Cancer Metastatic

## Interventions

- **RADIATION:** SBRT
- **DRUG:** Immunological Agent
- **DRUG:** Immunological Factors

## Key facts

- **NCT ID:** NCT02976740
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2019-06
- **Final completion:** 2019-12
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2016-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02976740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02976740, "SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02976740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*